Verastem Oncology said Wednesday that the Food and Drug Administration cleared the company's investigational new drug application for its potential treatment of certain cancers.

Dow and X-Energy Reactor Company announced the submission of a construction permit application to the Nuclear Regulatory Commission for a ...

JEE Advanced 2025 registration procedure will start soon. Eligible candidates will be able to register themselves for JEE Advanced 2025 by visiting the official website, jeeadv.ac.in. The ...

Dow (NYSE: DOW) and X-Energy Reactor Company, LLC ("X-energy") announced the submission of a construction permit application ...

Friedman’s study, which involved surveying 500 people with the illness, found that 75% of sufferers didn’t even realize there is now medicine — Cosentyx (secukinumab) — that’s been ...

If it’s meant to be, your application will be approved. But waiting can feel endless. Fortunately, many issuers, including Chase, allow you to check your application status and end the suspense.

Cosentyx belongs to a newer class of drugs that inhibit IL-17, and Novartis is aiming to encourage doctors to use it with longer term data showing that its benefits persist after five years, as ...

Ascentage Pharma (AAPG) announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology, ...

Apply for your desired Bachelor’s degree programme via eApply. Please complete the online application form fully and truthfully. You will be guided through the online application step by step. Please ...

The BE RADIANT trial pitted bimekizumab against Novartis’ Cosentyx (secukinumab) in the treatment of adults with moderate-to-severe psoriasis, and according to UCB is the first study to compare ...